Key Takeaways
- The 14 ANDAs submitted in October were the second-lowest monthly total in the GDUFA era.
The aftermath of an ANDA avalanche hit the US Food and Drug Administration in October, even though the actual crush...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?